Panagoutsos S - Search Results

1

Effects of L-carnitine on oxidative stress responses in patients with renal disease.

Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A, Michailidis Y, Jamurtas AZ, Mandalidis D, Taxildaris K, Vargemezis V. Fatouros IG, et al. Among authors: panagoutsos s. Med Sci Sports Exerc. 2010 Oct;42(10):1809-18. doi: 10.1249/MSS.0b013e3181dbacab. Med Sci Sports Exerc. 2010. PMID: 20216464 Clinical Trial.

2

Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy.

Vart P, Duivenvoorden R, Adema A, Covic A, Finne P, Braak NH, Laine K, Noordzij M, Schouten M, Jager KJ, Gansevoort RT; ERACODA Collaborators. Vart P, et al. Sci Rep. 2022 Oct 26;12(1):17978. doi: 10.1038/s41598-022-22657-4. Sci Rep. 2022. PMID: 36289317 Free PMC article.

3

Evaluation of CNS-function in CAPD patients using magnetoencephalography (MEG): comparison with hemodialysis patients.

Thodis E, Anninos PA, Pasadakis P, Adamopoulos AV, Panagoutsos S, Vargemezis V. Thodis E, et al. Among authors: panagoutsos s. Adv Perit Dial. 1992;8:181-4. Adv Perit Dial. 1992. PMID: 1361782

4

Treatment of CAPD peritonitis with clavulanate potentiated ticarcillin.

Pasadakis P, Thodis E, Euthimiadou A, Panagoutsos S, Oustoglou E, Kartali S, Vargemezis V. Pasadakis P, et al. Among authors: panagoutsos s. Adv Perit Dial. 1992;8:238-41. Adv Perit Dial. 1992. PMID: 1361796 Clinical Trial.

5

Treatment and prevention of relapses of CAPD Pseudomonas peritonitis.

Pasadakis P, Thodis E, Eftimimiadou A, Panagoutsos S, Papazoglou D, Kaliengidou M, Kartali S, Vargemezis V. Pasadakis P, et al. Among authors: panagoutsos s. Adv Perit Dial. 1993;9:206-10. Adv Perit Dial. 1993. PMID: 8105925

6

The identification of bone mineral density in CAPD in comparison with HD patients.

Pasadakis P, Thodis E, Manavis J, Mourvati E, Panagoutsos S, Vargemezis V. Pasadakis P, et al. Among authors: panagoutsos s. Adv Perit Dial. 1995;11:247-53. Adv Perit Dial. 1995. PMID: 8534716

7

Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.

Passadakis P, Panagoutsos S, Thodis E, Tsivara I, Sopassi F, Kartali S, Vargemezis V. Passadakis P, et al. Among authors: panagoutsos s. Adv Perit Dial. 1999;15:40-4. Adv Perit Dial. 1999. PMID: 10682070

8

Failure of icodextrin to provide adequate ultrafiltration in continuous ambulatory peritoneal dialysis patients.

Thodis E, Passadakis P, Panagoutsos S, Marinopoulos D, Vargemezis V. Thodis E, et al. Among authors: panagoutsos s. Adv Perit Dial. 1999;15:171-4. Adv Perit Dial. 1999. PMID: 10682096

9

Outcome for continuous ambulatory peritoneal dialysis patients is not predicted by peritoneal permeability characteristics.

Passadakis PS, Thodis ED, Panagoutsos SA, Selisiou CA, Pitta EM, Vargemezis VA. Passadakis PS, et al. Among authors: panagoutsos sa. Adv Perit Dial. 2000;16:2-6. Adv Perit Dial. 2000. PMID: 11045251

10

The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.

Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V. Thodis E, et al. Among authors: panagoutsos s. Adv Perit Dial. 2000;16:257-61. Adv Perit Dial. 2000. PMID: 11045306 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters